A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Sponsor
Genentech, Inc.
Study ID
NCT00556699
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — DRUG
    Escalating intravenous repeating dose
  • SGN-40 — DRUG
    Escalating intravenous repeating dose

Study Details

This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.

Key Dates

First listed
Nov 12, 2007
Start date
Dec 31, 2007
Status verified
Nov 2011
Primary completion
Nov 30, 2010
Completion
Nov 30, 2010

Study Design

Enrollment
22 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose [ Time Frame: Length of study ]

Related Studies